- Mepolizumab is a humanized monoclonal antibody targeting interleukin-5 (IL-5), primarily used in the treatment of eosinophilic-driven conditions such as severe eosinophilic asthma, EGPA (eosinophilic granulomatosis with polyangiitis), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP). It works by reducing eosinophil levels, which play a key role in inflammation and disease severity
- The global mepolizumab market is experiencing steady growth due to rising awareness and diagnosis of eosinophilic disorders, expanded regulatory approvals for multiple indications, and increased adoption of biologics in asthma and autoimmune disease management
- North America is expected to dominate the mepolizumab market with a market share of approximately 48.50%, driven by advanced healthcare infrastructure, high adoption rates of biologic therapies, and the strong presence of key pharmaceutical players
- Asia-Pacific is expected to be the fastest growing region in the mepolizumab market during the forecast period, driven by rapid expansion in healthcare infrastructure, increasing awareness about eosinophilic disorders, and growing adoption of biologic treatments
- Severe asthma segment is expected to dominate the market with a market share of 62.65% due to its high prevalence and established clinical use of biologic therapies. As a primary indication for mepolizumab, severe eosinophilic asthma accounts for the majority of prescriptions, supported by strong clinical evidence and guideline recommendations
